Surgery Partners Inc (SGRY)

Surgery Partners (SGRY) reported mixed Q2 2026 results with modest revenue growth but wider net losses, and significantly slower M&A activity than projected. This reinforces the importance of execution on higher acuity growth and highlights the risk posed by a slower deal pace and rising interest costs. The company's investment narrative now faces challenges in meeting its ambitious revenue and earnings forecasts without the anticipated acquisition-driven expansion.

Surgery Partners director Teresa DeLuca purchased 11,250 shares of the company's common stock for $161,212 on August 18, 2026. This transaction increased her beneficial ownership to 68,093 shares. The purchase occurred as the stock's value has recently declined, and the company has also reported Q2 2026 financial results, including a wider-than-expected loss but strong revenue and a significant hospital divestiture underway.

Teresa DeLuca, a director at Surgery Partners, Inc. (NASDAQ:SGRY), recently purchased 11,250 shares of the company's common stock for $161,212 at a price of $14.33 per share. This transaction, disclosed in an amended SEC filing, increased her total beneficial ownership to 68,093 shares, even as the stock's market price has since fallen to $13.94. The purchase follows the company's Q2 2026 financial results which showed a wider-than-expected loss but beat revenue forecasts, alongside a strategic plan to sell two hospitals for approximately $795 million.

Teresa DeLuca, a director at Surgery Partners, purchased 11,250 shares of the company's common stock for $161,212 on August 18, 2026, at a price of $14.33 per share. This transaction was disclosed in an amended SEC filing, correcting an earlier report. The purchase occurred while the stock was trading at $13.94, and InvestingPro data indicates a 7.3% decline in the stock over the past week, with a market capitalization of $1.76 billion.

Teresa Deluca, a director at Surgery Partners Inc (SGRY), recently purchased 10,000 shares at $14.35 each, increasing her total holdings to 66,843 shares and signaling confidence in the company. Despite this insider buying, the stock is classified as a "Possible Value Trap" by GuruFocus, trading significantly below its intrinsic value, which suggests investors should exercise caution. The mixed insider activity and balanced guru ownership indicate a cautious but not entirely negative outlook for the surgical services provider.